What Is GHRP-2? Benefits, Research & Safety
A potent growth hormone-releasing peptide that stimulates GH secretion through the ghrelin receptor, with additional effects on appetite and cortisol.
UK summary: Not a licensed UK medicine. Growth-hormone-releasing peptide. Prohibited at all times under WADA S2. Sometimes used in clinical research diagnostically (GH-stimulation testing), not as a therapy.
Quick Facts
Overview
GHRP-2 — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
Not a licensed UK medicine. Growth-hormone-releasing peptide. Prohibited at all times under WADA S2. Sometimes used in clinical research diagnostically (GH-stimulation testing), not as a therapy.
02Human evidence grade
03Preclinical evidence grade
04Regulatory status
- UK: Not licensed for human use. Research compound only.
- EU: Not approved for therapeutic use.
- Notes: GHRP-2 is approved in Japan as a diagnostic agent (Pralmorelin). It is not approved therapeutically anywhere. Prohibited in sports by WADA.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- Restores youthful GH levels safely.
- Effective treatment for sarcopenia or adult GH deficiency.
- Undetectable by WADA testing.
- Safe for daily long-term use.
07Common internet claims
- Marketed as a cleaner alternative to HGH for body composition.
- Sold by online retailers for stacking with CJC-1295.
- Promoted by 'anti-ageing' clinics for off-label use.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Used in NHS GH diagnostic testing — therefore safe” | C | Yes | High | GHRP-2 has a research / diagnostic history; that does not equate to a licensed therapy for healthy adults. |
| “Effective and safe long-term” | E | No | High | Long-term safety data in healthy adults is limited. |
| “Permitted for non-tested athletes” | E | No | High | Prohibited at all times under WADA S2; strict-liability rules apply regardless of testing schedule. |
09Safety uncertainty score
Limited human safety data; meaningful uncertainty about rare or long-term effects.
10Known adverse signals
- Cortisol and prolactin elevation (unlike Ipamorelin).
- Water retention, joint pain, carpal tunnel symptoms (GH-axis effects).
- Injection-site reactions.
- Theoretical oncologic risk from sustained IGF-1 elevation.
11Drug-interaction uncertainty
Interaction picture sparse; meaningful uncertainty when combined with other medicines.
12Anti-doping status
13UK legal position
Not licensed for human use. Research compound only.
14EU legal position
Not approved for therapeutic use.
15What this page cannot tell you
- Whether a UK-purchased vial contains GHRP-2 at the labelled concentration.
- How sustained cortisol elevation affects metabolic and immune outcomes.
- What the cancer risk profile is over years of off-label use.
- Whether it triggers WADA detection — assume yes, prohibition is strict-liability.
16Last reviewed
17Citation quality score
18Research gaps
- Diagnostic-test use does not translate to licensed therapeutic indication.
- Long-term outcome data in healthy adults absent.
- Combination-stack safety with CJC-1295, Ipamorelin uncharacterised.
- Cancer surveillance data unavailable.
19Safer alternatives / established care pathways
- Endocrinologist review with ITT or GHRH-arginine testing if adult GH deficiency is clinically suspected.
- Licensed recombinant HGH (Genotropin, Norditropin) under specialist supervision where genuine deficiency is confirmed.
- Resistance training and protein-adequate nutrition for body-composition goals.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is GHRP-2 a licensed UK medicine?
- What's the WADA / UKAD position?
- What licensed treatments exist for the underlying issue?
Discovery & History
Mechanism of Action
Researched Benefits
Based on preclinical and clinical research findings:
- 1Potent growth hormone release from the pituitary
- 2Elevated IGF-1 levels
- 3Potential improvements in body composition
- 4Possible enhancement of recovery and tissue repair
- 5Appetite stimulation (may benefit those needing to gain weight)
- 6Synergistic effects with GHRH analogues
Claim vs Evidence
How popular claims about GHRP-2 stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Used in NHS GH diagnostic testing — therefore safe” | C | Yes | High | GHRP-2 has a research / diagnostic history; that does not equate to a licensed therapy for healthy adults. |
| “Effective and safe long-term” | E | No | High | Long-term safety data in healthy adults is limited. |
| “Permitted for non-tested athletes” | E | No | High | Prohibited at all times under WADA S2; strict-liability rules apply regardless of testing schedule. |
Theoretical Dosing & Protocols
| Theoretical Dosage | 100-300 mcg per dose |
| Frequency | 2-3 times daily, typically before meals and at bedtime |
| Duration | Variable; often cycled |
| Notes | GHRP-2 is not approved for therapeutic use outside diagnostic applications. It causes more cortisol/prolactin release than Ipamorelin and more appetite stimulation. Any use should be under medical supervision. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection (most common)
- Intravenous (diagnostic use)
| Half-Life | Stability |
|---|---|
| Approximately 25-30 minutes | Lyophilised powder stable when properly stored; reconstituted solution should be refrigerated |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Increased appetite
- Water retention
- Injection site reactions
- Flushing
- Tingling or numbness
- Transient cortisol elevation
Rare Risks & Concerns
- Prolonged effects on cortisol with chronic use
- Potential effects on glucose metabolism
- Unknown long-term effects
- Theoretical concerns with tumour growth
Contraindications
- Active malignancy
- Pregnancy and breastfeeding
- Diabetes (monitor closely)
- Conditions exacerbated by cortisol elevation
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not licensed for human use. Research compound only.
🇪🇺 European Union
Not approved for therapeutic use.
Clinical Studies Summary
Effects of GHRP-2 and Cysteamine Administration on Growth Performance, Somatotropic Axis Hormone and Muscle Protein Deposition in Yaks (Bos grunniens) with Growth Retardation.
Growth retardation in yaks was primarily due to somatotropic axis hormones secretion deficiency. Both GHRP-2 and CS administration can accelerate growth performance and GH, IGF-1 secretion in yaks with growth retardation. GHRP-2 enhanced muscle protein deposition mainly by up-regulated the protein synthesis pathways, whereas CS worked mainly by down-regulated the ubiquitin-proteasome pathway.
Determinants of GH-releasing hormone and GH-releasing peptide synergy in men.
002). In conclusion, a paradigm examining GHRH-GHRP synergy under a sex steroid clamp reveals highly selective control of basal, pulsatile, and synergistic peptide-driven GH secretion by AVF, E(2), and IGF-I in healthy men.
The combined administration of GH-releasing peptide-2 (GHRP-2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP-2 alone.
Coadministration of GHRP-2, TRH and GnRH reactivated the GH, TSH and LH axes in prolonged critically ill men and evoked beneficial metabolic effects which were absent with GHRP-2 infusion alone and only partially present with GHRP-2 + TRH. These data underline the importance of correcting the multiple hormonal deficits in patients with prolonged critical illness to counteract the hypercatabolic state.
Tyr-Ala-Hexarelin, a synthetic octapeptide, possesses the same endocrine activities of Hexarelin and GHRP-2 in humans.
In conclusion, the present results demonstrate that in humans Tyr-Ala-HEX is a GH secretagogue as potent as HEX and GHRP-2, two GHRP-6 superanalogs. Tyr-Ala-HEX also shares with HEX and GHRP-2 the same PRL- ACTH- and cortisol-releasing activity.
Synergy of L-arginine and GHRP-2 stimulation of growth hormone in men and women: modulation by exercise.
Exercise potentiated the individual stimulatory actions of A and G, while blunting the relative magnitude of the synergistic (supra-additive) interaction observed at rest.
Treatment effects of intranasal growth hormone releasing peptide-2 in children with short stature.
GHBP concentrations rose significantly, from 439 +/- 63 pmol/l to 688 +/- 48 pmol/l. In this study, intranasal GHRP-2 administration was well tolerated, and produced a modest but significant increase in growth velocity.
Looking for GHRP-2?
Source research-grade GHRP-2 from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about GHRP-2
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is GHRP-2 a licensed UK medicine?
- What's the WADA / UKAD position?
- What licensed treatments exist for the underlying issue?
UK regulatory & safety context
Related Research Guides
Peptide Comparisons
Related Peptides
CJC-1295
A synthetic growth hormone-releasing hormone analogue designed for extended half-life and sustained growth hormone secretion.
Learn moreIpamorelin
A selective growth hormone-releasing peptide known for its favourable side effect profile, stimulating GH release without significantly affecting cortisol or prolactin.
Learn moreGHRP-6
The first clinically evaluated growth hormone-releasing peptide, notable for its potent GH release and pronounced appetite-stimulating effects.
Learn moreHexarelin
A potent growth hormone-releasing peptide with notable cardioprotective properties independent of GH release.
Learn more